BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 19931382)

  • 1. Comparability of antibody response to a booster dose of 7-valent pneumococcal conjugate vaccine in infants primed with either 2 or 3 doses.
    Rodenburg GD; van Gils EJ; Veenhoven RH; Jones N; Tcherniaeva I; Hak E; van Alphen L; Berbers GA; Sanders EA
    Vaccine; 2010 Feb; 28(5):1391-6. PubMed ID: 19931382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term antibody levels and booster responses in South African children immunized with nonavalent pneumococcal conjugate vaccine.
    Huebner RE; Mbelle N; Forrest B; Madore DV; Klugman KP
    Vaccine; 2004 Jul; 22(21-22):2696-700. PubMed ID: 15246599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IgG antibody concentrations after immunization with 11-valent mixed-carrier pneumococcal conjugate vaccine in efficacy trial against pneumonia among Filipino infants.
    Soininen A; Nohynek H; Lucero M; Jousimies K; Ugpo J; Williams G; Käyhty H;
    Vaccine; 2009 May; 27(20):2680-8. PubMed ID: 19428879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers.
    Goldblatt D; Southern J; Ashton L; Richmond P; Burbidge P; Tasevska J; Crowley-Luke A; Andrews N; Morris R; Borrow R; Cartwright K; Miller E
    Pediatr Infect Dis J; 2006 Apr; 25(4):312-9. PubMed ID: 16567982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of a 2-dose priming and booster vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine.
    Silfverdal SA; Hogh B; Bergsaker MR; Skerlikova H; Lommel P; Borys D; Schuerman L
    Pediatr Infect Dis J; 2009 Oct; 28(10):e276-82. PubMed ID: 20118683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of 10-valent pneumococcal nontypeable Haemophilus Influenzae Protein D Conjugate Vaccine when administered as catch-up vaccination to children 7 months to 5 years of age.
    Vesikari T; Karvonen A; Korhonen T; Karppa T; Sadeharju K; Fanic A; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2011 Aug; 30(8):e130-41. PubMed ID: 21540760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of pneumococcal conjugate vaccine immunogenicity among infants and toddlers in an American Indian PnCRM7 efficacy trial.
    O'Brien KL; Moisi J; Moulton LH; Madore D; Eick A; Reid R; Weatherholtz R; Millar E; Hu D; Hackell J; Kohberger R; Siber G; Santosham M
    J Infect Dis; 2007 Jul; 196(1):104-14. PubMed ID: 17538890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
    Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of a pneumococcal conjugate 7-valent vaccine in infants with sickle cell disease.
    Reinert P; Benkerrou M; de Montalembert M; Lesprit E; Abadie I; Bernaudin F; Doit C; Bingen E; Tetelboum R; Bonnet E
    Pediatr Infect Dis J; 2007 Dec; 26(12):1105-9. PubMed ID: 18043446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
    Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Antibody Response Following a Booster With Either a 10- or 13-valent Pneumococcal Conjugate Vaccine in Toddlers Primed With a 13-valent Pneumococcal Conjugate Vaccine in Early Infancy.
    Trück J; Jawad S; Goldblatt D; Roalfe L; Snape MD; Voysey M; Pollard AJ
    Pediatr Infect Dis J; 2016 Jul; 35(7):787-93. PubMed ID: 27088583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of a heptavalent pneumococcal conjugate vaccine in Apache and Navajo Indian, Alaska native, and non-native American children aged <2 years.
    Miernyk KM; Parkinson AJ; Rudolph KM; Petersen KM; Bulkow LR; Greenberg DP; Ward JI; Brenneman G; Reid R; Santosham M
    Clin Infect Dis; 2000 Jul; 31(1):34-41. PubMed ID: 10913393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant.
    Wuorimaa T; Dagan R; Väkeväinen M; Bailleux F; Haikala R; Yaich M; Eskola J; Käyhty H
    J Infect Dis; 2001 Nov; 184(9):1211-5. PubMed ID: 11598848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A murine model for the study of immune memory in response to pneumococcal conjugate vaccination.
    Moreno RL; Sampson JS; Romero-Steiner S; Wong B; Johnson SE; Ades E; Carlone GM
    Vaccine; 2004 Aug; 22(23-24):3069-79. PubMed ID: 15297057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of the American Academy of Pediatrics--recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients.
    Lin PL; Michaels MG; Green M; Mazariegos GV; Webber SA; Lawrence KS; Iurlano K; Greenberg DP
    Pediatrics; 2005 Jul; 116(1):160-7. PubMed ID: 15995047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunogenicity and reactogenicity of DTPa-IPV-HBV/Hib and DTPa-IPV/Hib vaccines coadministered with 7-valent pneumococcal conjugate vaccine as primary vaccination and booster in healthy infants, according to the French vaccination calendar].
    Reinert P; Dejos V; Clyti N; Abitbol V
    Arch Pediatr; 2008 Mar; 15(3):263-70. PubMed ID: 18272353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Greater antibody responses to an eleven valent mixed carrier diphtheria- or tetanus-conjugated pneumococcal vaccine in Filipino than in Finnish or Israeli infants.
    Puumalainen T; Dagan R; Wuorimaa T; Zeta-Capeding R; Lucero M; Ollgren J; Käyhty H; Nohynek H
    Pediatr Infect Dis J; 2003 Feb; 22(2):141-9. PubMed ID: 12586978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of alternative regimens of the conjugated 7-valent pneumococcal vaccine: a randomized controlled trial.
    Givon-Lavi N; Greenberg D; Dagan R
    Pediatr Infect Dis J; 2010 Aug; 29(8):756-62. PubMed ID: 20661103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory.
    de Roux A; Schmöle-Thoma B; Siber GR; Hackell JG; Kuhnke A; Ahlers N; Baker SA; Razmpour A; Emini EA; Fernsten PD; Gruber WC; Lockhart S; Burkhardt O; Welte T; Lode HM
    Clin Infect Dis; 2008 Apr; 46(7):1015-23. PubMed ID: 18444818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.